36016-39-4

Usage

Uses

Used in Chemical Synthesis:
1,1-Dimethylethyl [[(2,4,6-trimethylphenyl)sulphonyl]oxy]carbamate is used as a reagent for the enantioselective aziridination of α,β-unsaturated aldehydes. Its unique structure allows for the selective formation of chiral aziridines, which are important intermediates in the synthesis of various biologically active compounds and pharmaceuticals.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 1,1-dimethylethyl [[(2,4,6-trimethylphenyl)sulphonyl]oxy]carbamate may be utilized as a key intermediate in the development of new drugs. Its ability to form aziridines with high enantioselectivity makes it a valuable tool for creating chiral molecules with potential therapeutic applications.
Used in Research and Development:
1,1-dimethylethyl [[(2,4,6-trimethylphenyl)sulphonyl]oxy]carbamate is also used in research and development settings to study the effects of different substituents and functional groups on the reactivity and selectivity of carbamate derivatives. Understanding these effects can lead to the design of more efficient and selective catalysts or reagents for various chemical transformations.

Synthesis

2-Mesitylenesufonylchloride (2.00 g, 9.17 mmol) was added to a flame dried and argon purged round-bottom flask and dissolved in ether (18 mL), followed by the addition of N-Boc-hydroxylamine (1.47 g, 1100 mmol) The flask was cooled to 0° C and then TEA was added dropwise (1.3 mL). The reaction stirred for 2 hours at 0° C, at which all starting material had been converted as seen by TLC. The TEA-Cl, white solid, was filtered, and washed with ether. The filtrate was concentrated in vacuo, and purified via flash chromatography in 25/75 EtOAc/hexane gradient. Yield was quantitative, 2.16 g, white solid.

Purification Methods

Separation of 1,1-Dimethylethyl (((2,4,6-trimethylphenyl)sulphonyl)oxy)carbamate on Newcrom R1 HPLC column:1,1-Dimethylethyl (((2,4,6-trimethylphenyl)sulphonyl)oxy)carbamate can be analyzed by this reverse phase (RP) HPLC method with simple conditions. The mobile phase contains an acetonitrile (MeCN), water, and phosphoric acid. For Mass-Spec (MS) compatible applications the phosphoric acid needs to be replaced with formic acid. Smaller 3 μm particles columns available for fast UPLC applications. This liquid chromatography method is scalable and can be used for isolation impurities in preparative separation. It also suitable for pharmacokinetics.

InChI:InChI=1/C14H21NO5S/c1-9-7-10(2)12(11(3)8-9)21(17,18)20-15-13(16)19-14(4,5)6/h7-8H,1-6H3,(H,15,16)

Upstream product

• 773-64-8 2-mesitylenesulphonyl chloride 
• 36016-38-3 tert-Butyl N-hydroxycarbamate 
• 108-67-8 1,3,5-trimethyl-benzene 
• 4248-19-5 tert-butyl carbazate 

Downstream Products

• 55899-13-3 1-amino-3-bromopyridin-1-ium 2,4,6-trimethylbenzenesulfonate 
• 55899-02-0 3-methyl-N-aminopyridinium mesitylenesulfonate 
• 81211-89-4 1-amino-3-(dimethylamino)pyridin-1-ium 2,4,6-trimethylbenzenesulfonate 
• 81211-83-8 1-amino-5-methoxypyridinium 2,4,6-trimethylbenzenesulfonate 
• 39996-44-6 1-amino-3-cyanopyridin-1-ium 2,4,6-trimethylbenzenesulfonate 
• 40146-54-1 1-amino-3-(ethoxycarbonyl)pyridin-1-ium 2,4,6-trimethylbenzenesulfonate 
• 39996-49-1 3-acetyl-1-aminopyridin-1-ium 2,4,6-trimethylbenzenesulfonate 
• 1326216-43-6 1-amino-3-(trifluoromethyl)pyridin-1-ium 2,4,6-trimethylbenzenesulfonate 

Relevant academic research and scientific papers

Preparation, use, and safety of 0-mesitylenesulfonylhydroxylamine

The aminating reagent O-mesitylsulfonylhydroxylamine (MSH) has a known potential hazard since it contains high-energy functional groups in its structure. There are references in the literature that report several incidents involving the use of pure and crystalline MSH. The preparation and safe use of this reagent at kilo scale are described herein.

N-(4-FLUOROPHENYL)-5-PHENYL-[1,2,4] TRIAZOLO [1,5-A] PYRIDINE-2-CARBOXAMIDE DERIVATIVES AND THEIR SYNTHESIS THEREOF

The present invention relates to the development of novel N-(4-fluorophenyl)-5-phenyl- [1,2,4]triazolo[1,5-a]pyridine-2-carboxamide derivatives for their different pharmacological activities. It particularly relates to the development of N-(4-fluorophenyl)-5-phenyl- [1,2,4]triazolo[1,5-a]pyridine-2-carboxamide derivatives as antiviral, anticancer, antifungal, hypoglycemic, anti-tubercular, sedative, anti-type 2 diabetes activity. It specifically relates to the N-(4-fluorophenyl)-5-phenyl-[1,2,4]triazolo[1,5-a]pyridine-2-carboxamide derivatives for treatment of H37Rv and multidrug-resistant (MDR) strains of Mycobacterium tuberculosis (MTB). The present invention also relates to the process for synthesis of N-(4-fluorophenyl)- 5-phenyl-[1,2,4]triazolo[1,5-a]pyridine-2-carboxamide derivatives. The invention further relates to method for treatment of method for treatment of diseases such as tuberculosis, type 2 diabetes, bacterial, viral and fungal infections. Invention addresses the challenges in working with chemical processes and products by inventing novel reaction methodology that can maximize the desired products and minimize by-products, designing new synthetic schemes that can simplify operations in chemical productions and seeking nontoxic reagent that are inherently environmentally and ecologically benign. Synthesis of novel N-(4- fluorophenyl)-5-phenyl-[1,2,4]triazolo[1,5-a]pyridine-2-carboxamide derivatives is being employed to develop a novel synthetic methodology and their pharmacological applications. Novel series of N-(4-fluorophenyl)-5-phenyl-[1,2,4]triazolo[l,5-a]pyridine-2-carboxamide derivatives were designed synthesized evaluated for their in vitro anti-mycobacterial activity against H37Rv and multi-drug-resistant (MDR) strains of mycobacterium tuberculosis (MTB). All the synthesized compounds were characterized by spectroscopic methods like Mass, NMR and elemental analysis.

SUBSTITUTED 1,5-NAPHTHYRIDINES OR QUINOLINES AS ALK5 INHIBITORS

The present disclosure provides inhibitors of activin receptor-like kinase 5 (ALK5). Also disclosed are methods to modulate the activity of ALK5 and methods of treatment of disorders mediated by ALK5.

Pyrimidine-4 (3H)-ketone heterocyclic compound, preparation method thereof and application of pyrimidine-4 (3H)-ketone heterocyclic compound in medicine

The invention relates to pyrimidine-4 (3H)-ketone heterocyclic compounds suitable for inhibiting or regulating SHP2, a preparation method of the pyrimidine-4 (3H)-ketone heterocyclic compounds and application of the pyrimidine-4 (3H)-ketone heterocyclic compounds in medicine. Specifically, the invention relates to a compound as shown in a general formula (I) and a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing the compound or the pharmaceutically acceptable salt thereof, a method for treating and/or preventing related diseases mediated by SHP2, especially cancers by using the compound or the pharmaceutically acceptable salt thereof, and a preparation method of the compound or the pharmaceutically acceptable salt thereof. The invention also relates to application of the compound or the pharmaceutically acceptable salt thereof or a pharmaceutical composition containing the compound or the pharmaceutically acceptable salt thereof in preparation of drugs for treating and/or preventing SHP2-mediated related diseases. Wherein each substituent in the general formula (I) is as defined in the specification.

PYRIMIDINYL GROUP-CONTAINING TRICYCLIC COMPOUND SERVING AS C-MET INHIBITOR

Disclosed are a pyrimidinyl group-containing tricyclic compound and applications thereof in preparing a cancer-treating medicament. Specifically disclosed are a compound as represented by formula (I), a pharmaceutically acceptable salt of same, or an isomer thereof.

AROMATIC RING DERIVATIVE AS IMMUNOREGULATION AND PREPARATION METHOD AND APPLICATION OF AROMATIC RING DERIVATIVE

Relating to a compound represented by formula (I) and a pharmaceutically acceptable salt of the compound, and an application of the compound as an S1P1 agonist.

Pyrazole formaldoxime ether compound as well as preparation method and application thereof

The invention discloses a pyrazole formaldoxime ether compound as well as a preparation method and application thereof. The structural formula of the pyrazole formaldoxime ether compound is shown as the following formula I shown in the specification, wherein in the formula I, R1 represents at least one of hydrogen, C1-C6 alkyl, C1-C6 alkyl monosubstituted by halogen and C1-C6 alkyl polysubstitutedby halogen; R2 represents at least one of hydrogen, C1-C6 alkyl, C1-C6 alkyl monosubstituted or polysubstituted by halogen, aryl and substituted aryl; R3 represents at least one of phenyl, benzyl, substituted benzyl, substituted phenyl, an unsubstituted nitrogen and/or oxygen-containing heterocyclic group, a substituted nitrogen and/or oxygen-containing heterocyclic group, an unsubstituted C3-C8cycloalkyl group and a substituted C3-C8 cycloalkyl group. The pyrazole formaldoxime ether compound takes oxime ether as a main skeleton structure, is simple in preparation method, can be used for efficiently preventing and treating fungal diseases and oomycete diseases of farmland crops, and can be used for disease resistance management.

Direct synthesis of secondary amides from ketones through Beckmann rearrangement using O-(mesitylsulfonyl)hydroxylamine

The Beckmann rearrangement is a versatile method for the preparation of secondary amides from ketones via oxime intermediates and has been widely used in the synthesis of bioactive natural products and pharmaceuticals. Herein, we have developed a highly efficient direct method for the preparation of secondary amides and lactams from ketones using O-(mesitylsulfonyl)hydroxylamine (MSH). The reactions proceed rapidly at room temperature under mild condition without requiring any additive, and tolerate multiple functional groups. A simple aqueous work-up often furnished the products in excellent yield with high purity.

Substituted pyrazole fused ring derivative as well as preparation method and application thereof

The invention relates to the field of medicinal chemistry, and mainly relates to a compound represented by a formula I, a stereoisomer, a despinner, a tautomer, an isotope marker, NOx or a pharmaceutically acceptable salt thereof, a preparation method of the compound, and an application of the compound in preparation of a medicine for treating RET kinase mediated diseases.

FUSED PYRAZINE DERIVATIVES AS A2A / A2B INHIBITORS

This application relates to compounds of Formula (I) or pharmaceutically acceptable salts thereof, which modulate the activity of adenosine receptors, such as subtypes A2A and A2B receptors, and are useful in the treatment of diseases related to the activity of adenosine receptors including, for example, cancer, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases.